<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017546</url>
  </required_header>
  <id_info>
    <org_study_id>CYC065-03</org_study_id>
    <nct_id>NCT04017546</nct_id>
  </id_info>
  <brief_title>CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS</brief_title>
  <official_title>A Phase I Combination Study of CYC065 and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm, dose escalation study in patients with relapsed or
      refractory AML or MDS. Treatment will be administered on an outpatient basis and all patients
      will receive CYC065 over 4-hour infusion once every 2 weeks on Day 1 and Day 15 in
      combination with venetoclax. One treatment cycle is 4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 17, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>One to 6 patients will be entered at a given CYC065 dose level. Dose escalation will be 33% after at least one patient has completed the first treatment cycle without â‰¥ grade 2 toxicity considered by the investigator to be related to CYC065. Upon the first occurrence of grade 2 toxicity related to CYC065, at least 3 patients will be entered at each dose level. If no DLT is observed in any patients, dose escalation will continue to be 33%. If one of 3 patients experienced a DLT at a given dose level, dose escalation will continue at 25% until MTD is reached. If 2 or more patients experienced a DLT at a given dose level, dose escalation will be stopped. At least 6 patients will be treated at MTD.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD)</measure>
    <time_frame>At the end of cycle 1 (each cycle is 28 days)</time_frame>
    <description>Number of patients who experience dose-limiting toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic effect</measure>
    <time_frame>At the end of cycle 1 (each cycle is 28 days)</time_frame>
    <description>plasma drug level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic effect</measure>
    <time_frame>At the end of cycle 1 (each cycle is 28 days)</time_frame>
    <description>MCL-1 level in peripheral white blood cells</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Anti-tumor activity</measure>
    <time_frame>from the date of first dose of CYC065 to 4 weeks after the last dose of CYC065</time_frame>
    <description>Number of patients achieving complete remission, partial remission, hematological improvement as evaluated using International Working Group (IWG) response criteria</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">25</enrollment>
  <condition>AML</condition>
  <condition>MDS</condition>
  <arm_group>
    <arm_group_label>CYC065 and venetoclax</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CYC065 will be administered intravenously via 4-hour infusion on Day 1 and Day 15. Venetoclax will be taken daily on Day 1 through Day 15. One cycle will be 28 days or 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CYC065</intervention_name>
    <description>intravenous infusion</description>
    <arm_group_label>CYC065 and venetoclax</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>oral capsule</description>
    <arm_group_label>CYC065 and venetoclax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously treated AML or MDS based on WHO classification and having at least 10%
             blasts in peripheral blood

          -  ECOG 0-2

          -  Adequate renal function

          -  Adequate liver function

          -  INR &lt;=1.2 in patients not receiving chronic anticoagulation

          -  At least 2 weeks from prior cytotoxic chemotherapy, radiation therapy, major surgery
             or other investigational cancer therapy

          -  Agree to practice effective contraception

        Exclusion Criteria:

          -  AML is of the subtype of APL or extramedullary myeloid tumor without bone marrow
             involvment

          -  Known AML involvement in CNS that is symptomatic and active

          -  Currently receiving radiotherapy, biological therapy, or any other investigational
             agents

          -  Uncontrolled intercurrent illness

          -  Pregnant or lactating

          -  Known to be HIV-positive

          -  Known active hepatitis B and/or hepatitis C infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gautam Borthakur, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Judy Chiao, MD</last_name>
    <phone>9085177330</phone>
    <email>jchiao@cyclacel.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hind Alazzawi</last_name>
      <phone>713-794-4823</phone>
      <email>halazzawi@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Gautam Borthakur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 8, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CYC065</keyword>
  <keyword>CDK2/9</keyword>
  <keyword>venetoclax</keyword>
  <keyword>BCL-2</keyword>
  <keyword>MCL-1</keyword>
  <keyword>Relapsed</keyword>
  <keyword>Refractory</keyword>
  <keyword>acute myeloid leukemia</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>AML</keyword>
  <keyword>MDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

